Radiotherapy provider Varian Medical Systems has treated its first patient with its Gated RapidArc system, a radiotherapy treatment technology that monitors patient breathing and compensates for tumor motion.
Patients with metastatic non-small cell lung cancer (NSCLC) who received early palliative care lived two months longer than patients receiving standard care and reported improved mood and quality of life, according to a study in the Aug. 19 New England Journal of Medicine (NEJM).
Preradiotherapy FDG PET for non-small cell lung cancer (NSCLC) patients referred for 3D conformal radiotherapy may lead to significant modification of treatment strategy and radiotherapy planning, according to a prospective multicenter study published in the American Journal of Roentgenology.
Linear accelerator based stereotactic radiosurgery may be a promising therapeutic option for patients presenting with metastatic tumors in critical eloquent parts of the brain, according to a study presented at the 5th International Conference of the Novalis Circle held last month in Munich.
Friday, July 23 2010
PHILADELPHIA—Lung cancer patients treated with stereotactic body radiation therapy (SBRT) experienced few lasting side effects, indicating the technique adequately spares normal tissue, according to a six-year study presented July 19 at the annual meeting of the American Association of Physicists in Medicine (AAPM).
PHILADELPHIA--A new mathematical model to better pinpoint tumor location and thereby reduce radiation exposure uses data on how tumor motion has changed during a course of radiation treatment, along with real-time tumor images to calculate the confidence physicists can have about an instantaneous tumor position estimate. The research was presented July 21 at the annual meeting of the American Association of Physicists in Medicine (AAPM).
Vanderbilt University Medical Center in Nashville, Tenn., and affiliated VA Tennessee Valley Healthcare System has performed a specialized 68Ga-DOTATATE PET/CT scan to locate the presence of tumors.
Developing new imaging biomarkers and public data sets for lung cancer is important for independent peer review and verification of results, and new capabilities for the rapid assessment of treatment responses are required in order to allow for more rapid evaluation of the success or failure of drug candidates in clinical trials, according to a report published July in Optics Express.
Cancer mortality rates continued a 20 year drop, with 767,000 cancer deaths averted, according to a report from the American Cancer Society (ACS) published online July 7 in CA: A Cancer Journal for Clinicians.
Yashoda Hospital in Hyderabad, India, has treated a 65–year old inoperable lung cancer patient with stereotactic radiosurgery via RapidArc technology from Varian Medical Systems.
Shorter length of leukocyte telomeres–chromosome markers of biological aging–are associated with an increased risk of cancer and death from cancer, according to a study in the July 7 issue of Journal of the American Medical Association.
The principal investigators of the Radiation Therapy Oncology Group re-elected Walter J. Curran Jr., MD, to a fourth term as group chair.
A new lung cancer risk index could provide a way to determine an individual’s risk for lung cancer, according to a study published in the July issue of Academic Radiology. Researchers analyzed high-resolution CT datasets and pulmonary function testing results to produce a quantitative measure for estimating an individual’s lung cancer risk.
Written by C.P. Kaiser
Ten years ago, it was nearly impossible to go through the day without seeing an advertisement for whole-body CT screening. Today it’s a different story. The radiation dose exposure from CT scanning has come under intense scrutiny and the value of CT screening must be proved in rigorous trials before many payors, especially Medicare, will consider reimbursing for an exam.
The FDA has granted approval for Riverain Medical’s newest version of the OnGuard chest x-ray computer-aided detection (CAD) technology.
The phase I trial of the chemotherapy drug pemetrexed (Alimta, Eli Lilly) when used simultaneously with radiotherapy for certain cases of lung cancer has proven to be well-enough tolerated to allow for high dose administration during the treatment, increasing radiotherapy’s effectiveness, researchers reported during a presentation at the second annual European Lung Cancer Conference on April 30.
When treated with hyperfractionated or accelerated radiotherapy as opposed to a traditional combined radio-chemotherapy schedule, patients with both non-small-cell lung cancer and small-cell lung cancer benefit in terms of overall survival, according to the results of a meta-analysis presented at the second annual European Lung Cancer Conference (ELCC) last week.
A new 4D software program that combines the “breathing-adapted radiotherapy” technique will improve the treatment of lung cancer, said Nicolas Peguret, MD, and colleagues from Hôpitaux Universitaires de Genève during a presentation at the second annual European Lung Cancer Conference (ELCC) in Geneva last week.
According to a recently released report by the American Society for Radiation Oncology (ASTRO), stereotactic body radiotherapy (SBRT) in the treatment of lung cancer can be a reasonable alternative to surgery in certain cases of the disease.
For lung cancer tumors with a diameter of 6.8 to 50.7 mm found during CT screenings, a detection rate of 94 percent could be achieved with chest radiography only at the expense of a high false-positive rate and an excessive number of work-up CT examinations, according to the findings of a study published in the May edition of Radiology.
|